

# Napoleone Ferrara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5759986/publications.pdf>

Version: 2024-02-01

227  
papers

95,305  
citations

765

123  
h-index

1631

221  
g-index

235  
all docs

235  
docs citations

235  
times ranked

72573  
citing authors

#	ARTICLE	IF	CITATIONS
1	LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy. <i>EMBO Molecular Medicine</i> , 2022, 14, e14511.	3.3	11
2	Vascular heterogeneity: VEGF receptors make blood vessels special. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	12
3	Naturally occurring combinations of receptors from single cell transcriptomics in endothelial cells. <i>Scientific Reports</i> , 2022, 12, 5807.	1.6	2
4	Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
5	Tipifarnib as a Precision Therapy for <i>HRAS</i> -Mutant Head and Neck Squamous Cell Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1784-1796.	1.9	72
6	Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21598-21608.	3.3	46
7	Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways. <i>Nature Communications</i> , 2020, 11, 6330.	5.8	20
8	Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune Cells. <i>Frontiers in Immunology</i> , 2020, 11, 626812.	2.2	29
9	VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264.	13.5	1,468
10	Interleukin-22 promotes tumor angiogenesis. <i>Angiogenesis</i> , 2019, 22, 311-323.	3.7	60
11	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 211-226.		5
12	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 1-16.		0
13	Introduction by the Guest Editors. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 163-164.	1.0	0
14	Metastatic growth instructed by neutrophil-derived transferrin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11060-11065.	3.3	56
15	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
16	The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. <i>Physiological Reviews</i> , 2018, 98, 1055-1082.	13.1	65
17	Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. <i>Nature Cell Biology</i> , 2017, 19, 915-927.	4.6	271
18	Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	8

#	ARTICLE	IF	CITATIONS
19	Outer retinal tubulations response to anti-VEGF treatment. British Journal of Ophthalmology, 2016, 100, 819-823.	2.1	14
20	Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. Cell, 2016, 165, 882-895.	13.5	167
21	Commentary on "Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" Cancer Research, 2016, 76, 4913-4915.	0.4	3
22	Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell, 2016, 167, 275-284.e6.	13.5	58
23	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	21.5	724
24	The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunology Research, 2016, 4, 83-91.	1.6	290
25	Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Neuro-Oncology, 2016, 18, 939-949.	0.6	38
26	Loss of Vascular Endothelial Growth Factor A (VEGFA) Isoforms in Granulosa Cells Using pDmrt-1-Cre or Amhr2-Cre Reduces Fertility by Arresting Follicular Development and by Reducing Litter Size in Female Mice. PLoS ONE, 2015, 10, e0116332.	1.1	24
27	A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain. Cancer Cell, 2015, 27, 780-796.	7.7	97
28	Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells. Cardiovascular Diabetology, 2015, 14, 19.	2.7	23
29	A Message from the New Editor-in-Chief. Molecular Cancer Therapeutics, 2014, 13, 3-4.	1.9	0
30	Endothelial cells regulate neural crest and second heart field morphogenesis. Biology Open, 2014, 3, 679-688.	0.6	19
31	Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice. Journal of Vascular Surgery, 2014, 59, 1402-1409.e4.	0.6	33
32	Inhibiting the Response to VEGF in Diabetes. Science Signaling, 2014, 7, pe1.	1.6	11
33	VEGF modulates synaptic activity in the developing spinal cord. Developmental Neurobiology, 2014, 74, 1110-1122.	1.5	9
34	Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A. Molecular Pharmaceutics, 2014, 11, 3421-3430.	2.3	73
35	An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine, 2013, 19, 1114-1123.	15.2	395
36	Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response. Neoplasia, 2013, 15, 694-IN4.	2.3	27

#	ARTICLE	IF	CITATIONS
37	Vascular Endothelial Growth Factor A in Intraocular Vascular Disease. <i>Ophthalmology</i> , 2013, 120, 106-114.	2.5	334
38	<sc>VEGF</sc>â€œ<sc>A</sc> regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. <i>EMBO Molecular Medicine</i> , 2013, 5, 1415-1430.	3.3	141
39	A direct and melanopsin-dependent fetal light response regulates mouse eye development. <i>Nature</i> , 2013, 494, 243-246.	13.7	183
40	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. <i>Cell</i> , 2013, 152, 1065-1076.	13.5	209
41	Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases. <i>Science Signaling</i> , 2013, 6, ra25.	1.6	62
42	Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12. <i>Clinical Cancer Research</i> , 2013, 19, 4433-4445.	3.2	33
43	Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 3681-3692.	3.2	53
44	Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSFâ€œinduced neutrophil recruitment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6079-6084.	3.3	101
45	Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. <i>Blood</i> , 2013, 121, 2574-2578.	0.6	52
46	Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. <i>ELife</i> , 2013, 2, e00324.	2.8	75
47	Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 19574-19584.	1.6	76
48	Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function. <i>Cell</i> , 2012, 151, 384-399.	13.5	144
49	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. <i>Nature Biotechnology</i> , 2012, 30, 648-657.	9.4	95
50	Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. <i>Journal of Clinical Investigation</i> , 2012, 122, 2454-2468.	3.9	533
51	Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. <i>EMBO Journal</i> , 2012, 31, 3513-3523.	3.5	411
52	Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. <i>Journal of Clinical Investigation</i> , 2012, 122, 3101-3113.	3.9	309
53	Comparing protein VEGF inhibitors: In vitro biological studies. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 276-281.	1.0	82
54	Developmental and Pathological Angiogenesis. <i>Annual Review of Cell and Developmental Biology</i> , 2011, 27, 563-584.	4.0	620

#	ARTICLE	IF	CITATIONS
55	From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara. <i>International Journal of Developmental Biology</i> , 2011, 55, 383-388.	0.3	37
56	Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. <i>Nature</i> , 2011, 474, 511-515.	13.7	244
57	Multiple Effects of Angiopoietin-2 Blockade on Tumors. <i>Cancer Cell</i> , 2011, 19, 431-433.	7.7	21
58	Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11590-11595.	3.3	93
59	Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. <i>Nature Medicine</i> , 2010, 16, 1107-1111.	15.2	184
60	Targeting the tumour vasculature: insights from physiological angiogenesis. <i>Nature Reviews Cancer</i> , 2010, 10, 505-514.	12.8	648
61	Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. <i>Current Opinion in Hematology</i> , 2010, 17, 1.	1.2	120
62	Stromal Cell-Derived Factor-1/CXCL12 Contributes to MMTV-Wnt1 Tumor Growth Involving Gr1+CD11b+ Cells. <i>PLoS ONE</i> , 2010, 5, e8611.	1.1	30
63	Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action. <i>Molecular Biology of the Cell</i> , 2010, 21, 687-690.	0.9	209
64	A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life. <i>Cancer Research</i> , 2010, 70, 3269-3277.	0.4	91
65	Targeting the Tumor Microenvironment With Src Kinase Inhibition. <i>Clinical Cancer Research</i> , 2010, 16, 775-777.	3.2	8
66	Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21248-21255.	3.3	546
67	Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 224-235.	1.2	93
68	Functions of Type II Pneumocyte-Derived Vascular Endothelial Growth Factor in Alveolar Structure, Acute Inflammation, and Vascular Permeability. <i>American Journal of Pathology</i> , 2010, 176, 1725-1734.	1.9	42
69	Pathways mediating VEGF-independent tumor angiogenesis. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 21-26.	3.2	273
70	Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development. <i>Cell</i> , 2010, 140, 268-279.	13.5	311
71	PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth. <i>Cell</i> , 2010, 141, 166-177.	13.5	145
72	Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors. <i>American Journal of Pathology</i> , 2010, 176, 1564-1576.	1.9	137

#	ARTICLE	IF	CITATIONS
73	Astrocyte-Derived Vascular Endothelial Growth Factor Stabilizes Vessels in the Developing Retinal Vasculature. PLoS ONE, 2010, 5, e11863.	1.1	120
74	VEGF-A: a critical regulator of blood vessel growth. European Cytokine Network, 2009, 20, 158-163.	1.1	281
75	Characterization and Regulation of Bv8 in Human Blood Cells. Clinical Cancer Research, 2009, 15, 2675-2684.	3.2	71
76	Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. Clinical Cancer Research, 2009, 15, 6674-6682.	3.2	142
77	PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment. Cancer Cell, 2009, 15, 21-34.	7.7	527
78	VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research, 2009, 335, 261-269.	1.5	179
79	Vascular Endothelial Growth Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 789-791.	1.1	536
80	G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6742-6747.	3.3	442
81	Local Guidance of Emerging Vessel Sprouts Requires Soluble Flt-1. Developmental Cell, 2009, 17, 377-386.	3.1	213
82	The Molecular Basis of Vascular Lumen Formation in the Developing Mouse Aorta. Developmental Cell, 2009, 17, 505-515.	3.1	315
83	The function of VEGF-A in lens development: Formation of the hyaloid capillary network and protection against transient nuclear cataracts. Experimental Eye Research, 2009, 88, 270-276.	1.2	22
84	Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends in Pharmacological Sciences, 2009, 30, 624-630.	4.0	137
85	Role of myeloid cells in tumor angiogenesis and growth. Trends in Cell Biology, 2008, 18, 372-378.	3.6	149
86	VEGF Inhibition and Renal Thrombotic Microangiopathy. New England Journal of Medicine, 2008, 358, 1129-1136.	13.9	1,348
87	Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resistance Updates, 2008, 11, 219-230.	6.5	104
88	Effects of an Anti-VEGF-A Monoclonal Antibody on Laser-Induced Choroidal Neovascularization in Mice: Optimizing Methods to Quantify Vascular Changes. , 2008, 49, 1178.		70
89	Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1. Clinical Cancer Research, 2008, 14, 249-258.	3.2	55
90	Interaction between Bevacizumab and Murine VEGF-A: A Reassessment. , 2008, 49, 522.		149

#	ARTICLE	IF	CITATIONS
91	Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2640-2645.	3.3	275
92	Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells: Figure 1.. Cancer Research, 2008, 68, 5501-5504.	0.4	154
93	Remembering Jean Plouet, Pioneer of Angiogenesis Research in France and Co-Discoverer of Vascular Endothelial Growth Factor. Cancer Research, 2008, 68, 10004-10004.	0.4	0
94	Chapter 6 Mouse Models to Investigate Anti-Cancer Effects of VEGF Inhibitors. Methods in Enzymology, 2008, 445, 125-139.	0.4	2
95	Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3478-3483.	3.3	107
96	Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. Annual Review of Medicine, 2007, 58, 491-504.	5.0	227
97	Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 10625-10630.	3.3	64
98	Antiangiogenic Therapy for Cancer: An Update. Cancer Journal (Sudbury, Mass ), 2007, 13, 345-348.	1.0	59
99	Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Developmental Biology, 2007, 308, 44-53.	0.9	142
100	Autocrine VEGF Signaling Is Required for Vascular Homeostasis. Cell, 2007, 130, 691-703.	13.5	902
101	Endothelium-Microenvironment Interactions in the Developing Embryo and in the Adult. Developmental Cell, 2007, 12, 181-194.	3.1	128
102	Function Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage Library. Journal of Molecular Biology, 2007, 366, 815-829.	2.0	108
103	Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnology, 2007, 25, 911-920.	9.4	795
104	Antiangiogenesis to treat cancer and intraocular neovascular disorders. Laboratory Investigation, 2007, 87, 227-230.	1.7	56
105	Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature, 2007, 450, 825-831.	13.7	582
106	Vascular targeting via caveolae. Nature Biotechnology, 2007, 25, 431-432.	9.4	8
107	Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective: Fig. 1.. Clinical Cancer Research, 2006, 12, 5018-5022.	3.2	511
108	The Vascular Basement Membrane: A Niche for Insulin Gene Expression and $\beta$ 2 Cell Proliferation. Developmental Cell, 2006, 10, 397-405.	3.1	463

#	ARTICLE	IF	CITATIONS
109	Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. <i>Blood</i> , 2006, 107, 550-557.	0.6	37
110	Paracrine VEGF/VE-Cadherin Action on Ovarian Cancer Permeability. <i>Experimental Biology and Medicine</i> , 2006, 231, 1646-1652.	1.1	11
111	Corneal avascularity is due to soluble VEGF receptor-1. <i>Nature</i> , 2006, 443, 993-997.	13.7	605
112	Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 724-735.	3.0	217
113	Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF. <i>Journal of Biological Chemistry</i> , 2006, 281, 951-961.	1.6	315
114	Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor $\hat{I}\pm$ Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 2676-2688.	3.2	112
115	DEVELOPMENT OF RANIBIZUMAB, AN ANTI-“VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 859-870.	1.0	753
116	Imaging tumor angiogenesis. <i>Journal of Clinical Investigation</i> , 2006, 116, 2585-2587.	3.9	18
117	Angiogenesis as a therapeutic target. <i>Nature</i> , 2005, 438, 967-974.	13.7	2,384
118	Angiogenic inhibitors: a new therapeutic strategy in oncology. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 562-577.	4.3	186
119	Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 328-335.	1.0	875
120	Vascular Endothelial Growth Factor Expression in the Retinal Pigment Epithelium Is Essential for Choriocapillaris Development and Visual Function. <i>American Journal of Pathology</i> , 2005, 167, 1451-1459.	1.9	322
121	Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature. <i>Mechanisms of Development</i> , 2005, 122, 877-886.	1.7	65
122	Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. <i>Cancer Research</i> , 2005, 65, 671-80.	0.4	427
123	Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. <i>Thrombosis and Haemostasis</i> , 2004, 91, 595-605.	1.8	179
124	Human Endocrine Gland-Derived Vascular Endothelial Growth Factor: Expression Early in Development and in Leydig Cell Tumors Suggests Roles in Normal and Pathological Testis Angiogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4078-4088.	1.8	63
125	Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia. <i>Circulation</i> , 2004, 110, 2436-2443.	1.6	172
126	Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16813-16818.	3.3	205



#	ARTICLE	IF	CITATIONS
127	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 391-400.	21.5	2,211
128	VEGF-null cells require PDGFR $\beta$ signaling-mediated stromal fibroblast recruitment for tumorigenesis. <i>EMBO Journal</i> , 2004, 23, 2800-2810.	3.5	289
129	Loss of HIF-1 $\alpha$ in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. <i>Cancer Cell</i> , 2004, 6, 485-495.	7.7	494
130	Decrease in Tumor Apparent Permeability-Surface Area Product to a MRI Macromolecular Contrast Medium Following Angiogenesis Inhibition with Correlations to Cytotoxic Drug Accumulation. <i>Microcirculation</i> , 2004, 11, 387-396.	1.0	35
131	EG-VEGF: A Novel Mediator of Endocrine-Specific Angiogenesis, Endothelial Phenotype, and Function. <i>Annals of the New York Academy of Sciences</i> , 2004, 1014, 50-57.	1.8	24
132	Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. <i>Prostate</i> , 2004, 58, 57-65.	1.2	42
133	Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2335-2342.	13.9	9,850
134	Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. <i>Endocrine Reviews</i> , 2004, 25, 581-611.	8.9	3,152
135	VEGF and its receptors. <i>International Congress Series</i> , 2004, 1262, 283-286.	0.2	3
136	The role of VEGF in normal and neoplastic hematopoiesis. <i>Journal of Molecular Medicine</i> , 2003, 81, 20-31.	1.7	173
137	Role of VEGF-A in Vascularization of Pancreatic Islets. <i>Current Biology</i> , 2003, 13, 1070-1074.	1.8	351
138	EG-VEGF and Bv8A Novel Family of Tissue-Selective Mediators of Angiogenesis, Endothelial Phenotype, and Function. <i>Trends in Cardiovascular Medicine</i> , 2003, 13, 276-282.	2.3	50
139	The hypoxic response of tumors is dependent on their microenvironment. <i>Cancer Cell</i> , 2003, 4, 133-146.	7.7	375
140	The biology of VEGF and its receptors. <i>Nature Medicine</i> , 2003, 9, 669-676.	15.2	8,501
141	Differential Expression of the Angiogenic Factor Genes Vascular Endothelial Growth Factor (VEGF) and Endocrine Gland-Derived VEGF in Normal and Polycystic Human Ovaries. <i>American Journal of Pathology</i> , 2003, 162, 1881-1893.	1.9	177
142	HIF-1 $\alpha$ Is Essential for Myeloid Cell-Mediated Inflammation. <i>Cell</i> , 2003, 112, 645-657.	13.5	1,862
143	Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. <i>Developmental Biology</i> , 2003, 262, 225-241.	0.9	243
144	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C $\beta$ and VEGF-A-induced angiogenesis in vitro. <i>Experimental Cell Research</i> , 2003, 285, 286-298.	1.2	39

#	ARTICLE	IF	CITATIONS
145	Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1. <i>Science</i> , 2003, 299, 890-893.	6.0	612
146	The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2685-2690.	3.3	184
147	Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. <i>Journal of Clinical Investigation</i> , 2003, 111, 707-716.	3.9	1,100
148	Characterization of Endocrine Gland-derived Vascular Endothelial Growth Factor Signaling in Adrenal Cortex Capillary Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 8724-8729.	1.6	90
149	Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9656-9661.	3.3	1,216
150	ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin $\alpha_5\beta_3$ and Induces Blood Vessel Formation in Vivo. <i>Journal of Biological Chemistry</i> , 2002, 277, 17281-17290.	1.6	204
151	ENDOCRINE GLAND VASCULAR ENDOTHELIAL GROWTH FACTOR (EG-VEGF) AND THE HYPOTHESIS OF TISSUE-SPECIFIC REGULATION OF ANGIOGENESIS. <i>Endocrine Research</i> , 2002, 28, 763-764.	0.6	13
152	Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer. <i>American Journal of Pathology</i> , 2002, 161, 1917-1924.	1.9	153
153	EG-VEGF and the concept of tissue-specific angiogenic growth factors. <i>Seminars in Cell and Developmental Biology</i> , 2002, 13, 3-8.	2.3	39
154	VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic $\beta$ cell carcinogenesis. <i>Cancer Cell</i> , 2002, 1, 193-202.	7.7	372
155	VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. <i>Nature</i> , 2002, 417, 954-958.	13.7	647
156	Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. <i>Nature Medicine</i> , 2002, 8, 913-917.	15.2	103
157	VEGF and the quest for tumour angiogenesis factors. <i>Nature Reviews Cancer</i> , 2002, 2, 795-803.	12.8	1,363
158	Identification of an Angiogenic Mitogen Selective for Endocrine Gland Endothelium. <i>Obstetrical and Gynecological Survey</i> , 2002, 57, 32-34.	0.2	1
159	Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo. <i>American Journal of Pathology</i> , 2001, 158, 1111-1120.	1.9	345
160	Role of vascular endothelial growth factor in regulation of physiological angiogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 280, C1358-C1366.	2.1	913
161	Identification of an angiogenic mitogen selective for endocrine gland endothelium. <i>Nature</i> , 2001, 412, 877-884.	13.7	519
162	Lysophosphatidic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2001, 93, 762-767.	3.0	224

#	ARTICLE	IF	CITATIONS
163	Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis. <i>Journal of Virology</i> , 2001, 75, 9828-9835.	1.5	175
164	The Role of Vascular Endothelial Growth Factor in Angiogenesis. <i>Acta Haematologica</i> , 2001, 106, 148-156.	0.7	385
165	Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). <i>Journal of Biological Chemistry</i> , 2001, 276, 3222-3230.	1.6	532
166	Formation of endothelial cell networks. <i>Nature</i> , 2000, 405, 139-141.	13.7	161
167	VEGF: an update on biological and therapeutic aspects. <i>Current Opinion in Biotechnology</i> , 2000, 11, 617-624.	3.3	351
168	Angiogenesis and Bone Growth. <i>Trends in Cardiovascular Medicine</i> , 2000, 10, 223-228.	2.3	321
169	A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3-kinase activation and endothelial cell migration. <i>EMBO Journal</i> , 2000, 19, 4064-4073.	3.5	157
170	VEGF Regulates Cell Behavior during Vasculogenesis. <i>Developmental Biology</i> , 2000, 224, 178-188.	0.9	113
171	Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans. <i>Toxicologic Pathology</i> , 1999, 27, 14-21.	0.9	81
172	Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration. <i>Toxicologic Pathology</i> , 1999, 27, 536-544.	0.9	337
173	Role of vascular endothelial growth factor in the regulation of angiogenesis. <i>Kidney International</i> , 1999, 56, 794-814.	2.6	640
174	Clinical applications of angiogenic growth factors and their inhibitors. <i>Nature Medicine</i> , 1999, 5, 1359-1364.	15.2	958
175	VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. <i>Nature Medicine</i> , 1999, 5, 623-628.	15.2	1,853
176	Molecular and biological properties of vascular endothelial growth factor. <i>Journal of Molecular Medicine</i> , 1999, 77, 527-543.	1.7	1,007
177	Vascular Endothelial Growth Factor Molecular and Biological Aspects. <i>Advances in Organ Biology</i> , 1999, 7, 25-57.	0.1	8
178	OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF). <i>Biochemical and Biophysical Research Communications</i> , 1999, 254, 480-483.	1.0	37
179	VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. <i>Journal of Clinical Investigation</i> , 1999, 104, 1613-1620.	3.9	421
180	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , 1998, 2, 203-217.	3.7	26

#	ARTICLE	IF	CITATIONS
181	Vascular endothelial growth factor is essential for corpus luteum angiogenesis. <i>Nature Medicine</i> , 1998, 4, 336-340.	15.2	581
182	Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. , 1998, 35, 1-10.		211
183	Mapping the Charged Residues in the Second Immunoglobulin-like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability. <i>Journal of Biological Chemistry</i> , 1998, 273, 3216-3222.	1.6	43
184	Role of Vascular Endothelial Growth Factor in Ovarian Cancer. <i>American Journal of Pathology</i> , 1998, 153, 1249-1256.	1.9	363
185	Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3-kinase/Akt Signal Transduction Pathway. <i>Journal of Biological Chemistry</i> , 1998, 273, 30336-30343.	1.6	1,736
186	Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 13313-13316.	1.6	834
187	Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro. <i>Journal of Biological Chemistry</i> , 1998, 273, 29979-29985.	1.6	181
188	Tumor Necrosis Factor- $\alpha$ Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 22128-22135.	1.6	232
189	Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes. <i>Journal of Biological Chemistry</i> , 1997, 272, 23659-23667.	1.6	667
190	Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1997, 3, 3-10.	0.8	16
191	Vascular Endothelial Growth Factor Attenuates Myocardial Ischemia-Reperfusion Injury. <i>Annals of Thoracic Surgery</i> , 1997, 64, 993-998.	0.7	95
192	Therapeutic Angiogenesis Following Arterial Gene Transfer of Vascular Endothelial Growth Factor in a Rabbit Model of Hindlimb Ischemia. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 628-635.	1.0	157
193	Vascular endothelial growth factor, a specific regulator of angiogenesis. <i>Current Opinion in Nephrology and Hypertension</i> , 1996, 5, 35-44.	1.0	149
194	Crystallization of the receptor binding domain of vascular endothelial growth factor. , 1996, 26, 353-357.		45
195	Natural killer cells, adhesion and tumor angiogenesis. <i>Nature Medicine</i> , 1996, 2, 971-972.	15.2	14
196	Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. <i>Nature</i> , 1996, 380, 439-442.	18.7	3,312
197	Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma. <i>Journal of Biological Chemistry</i> , 1996, 271, 29483-29488.	1.6	224
198	The Carboxyl-terminal Domain(111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency. <i>Journal of Biological Chemistry</i> , 1996, 271, 7788-7795.	1.6	534

#	ARTICLE	IF	CITATIONS
199	Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors. <i>Journal of Biological Chemistry</i> , 1996, 271, 5638-5646.	1.6	427
200	Vascular Endothelial Growth Factor Augments Muscle Blood Flow and Function in a Rabbit Model of Chronic Hindlimb Ischemia. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 91-98.	0.8	82
201	Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac Performance. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 838-844.	0.8	228
202	The role of vascular endothelial growth factor in pathological angiogenesis. <i>Breast Cancer Research and Treatment</i> , 1995, 36, 127-137.	1.1	387
203	Missing link in angiogenesis. <i>Nature</i> , 1995, 376, 467-467.	13.7	44
204	Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 9709-9716.	1.6	237
205	Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. <i>Journal of Vascular Surgery</i> , 1995, 21, 314-325.	0.6	197
206	Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery. <i>Circulation</i> , 1995, 91, 2793-2801.	1.6	417
207	Recovery of Disturbed Endothelium-Dependent Flow in the Collateral-Perfused Rabbit Ischemic Hindlimb After Administration of Vascular Endothelial Growth Factor. <i>Circulation</i> , 1995, 91, 2802-2809.	1.6	106
208	Vascular Endothelial Growth Factor Receptor Localization and Activation in Human Trophoblast and Choriocarcinoma Cells. <i>Biology of Reproduction</i> , 1994, 51, 524-530.	1.2	232
209	Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. <i>New England Journal of Medicine</i> , 1994, 331, 1480-1487.	13.9	3,519
210	Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. <i>Nature</i> , 1993, 362, 841-844.	13.7	3,379
211	Vascular endothelial growth factor. <i>Trends in Cardiovascular Medicine</i> , 1993, 3, 244-250.	2.3	162
212	Leukemia Inhibitory Factor Expression in Human Carotid Plaques: Possible Mechanism for Inhibition of Large Vessel Endothelial Regrowth. <i>Growth Factors</i> , 1993, 9, 301-305.	0.5	16
213	The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies. <i>Growth Factors</i> , 1992, 7, 53-64.	0.5	282
214	Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. <i>Journal of Cellular Physiology</i> , 1992, 153, 557-562.	2.0	465
215	The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA. <i>Molecular Endocrinology</i> , 1991, 5, 1806-1814.	3.7	1,242
216	Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. <i>Methods in Enzymology</i> , 1991, 198, 391-405.	0.4	88

#	ARTICLE	IF	CITATIONS
217	The vascular endothelial growth factor family of polypeptides. <i>Journal of Cellular Biochemistry</i> , 1991, 47, 211-218.	1.2	542
218	Aortic Smooth Muscle Cells Express and Secrete Vascular Endothelial Growth Factor. <i>Growth Factors</i> , 1991, 5, 141-148.	0.5	138
219	Conditioned Medium from Mouse Sarcoma 180 Cells Contains Vascular Endothelial Growth Factor. <i>Growth Factors</i> , 1990, 4, 53-59.	0.5	96
220	Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 1989, 161, 851-858.	1.0	2,047
221	Fibroblast growth factor and the control of pituitary and gonad development and function. <i>The Journal of Steroid Biochemistry</i> , 1989, 32, 183-191.	1.3	40
222	Basic fibroblast growth factor: Expression in cultured cells derived from corneal endothelium and lens epithelium. <i>Experimental Eye Research</i> , 1988, 46, 71-80.	1.2	67
223	Regulation of ion transport in hypophysial pars intermedia follicular cell monolayers. <i>Biochemical and Biophysical Research Communications</i> , 1988, 157, 1376-1382.	1.0	11
224	[16] Culture and characterization of follicular cells of the bovine anterior pituitary and pars tuberalis. <i>Methods in Enzymology</i> , 1986, 124, 245-253.	0.4	16
225	Influence of sex steroids and prolactin on haloperidol-induced catalepsy. <i>Brain Research</i> , 1983, 279, 352-358.	1.1	29
226	Comparative effects of estrogens and prolactin on nigral and striatal GAD activity. <i>Brain Research</i> , 1982, 232, 238-241.	1.1	34
227	Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins. , 0, .		137